Tags

Type your tag names separated by a space and hit enter

Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.
Cell Rep. 2021 07 13; 36(2):109385.CR

Abstract

Administration of convalescent plasma or neutralizing monoclonal antibodies (mAbs) is a potent therapeutic option for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, SARS-CoV-2 variants with mutations in the spike protein have emerged in many countries. To evaluate the efficacy of neutralizing antibodies induced in convalescent patients against emerging variants, we isolate anti-spike mAbs from two convalescent COVID-19 patients infected with prototypic SARS-CoV-2 by single-cell sorting of immunoglobulin-G-positive (IgG+) memory B cells. Anti-spike antibody induction is robust in these patients, and five mAbs have potent neutralizing activities. The efficacy of most neutralizing mAbs and convalescent plasma samples is maintained against B.1.1.7 and mink cluster 5 variants but is significantly decreased against variants B.1.351 from South Africa and P.1 from Brazil. However, mAbs with a high affinity for the receptor-binding domain remain effective against these neutralization-resistant variants. Rapid spread of these variants significantly impacts antibody-based therapies and vaccine strategies against SARS-CoV-2.

Links

PMC Free PDF
PMC Free Full Text
FREE Publisher Full Text

Authors+Show Affiliations

Kaku Y
Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Kuwata T
Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan. Electronic address: tkuwata@kumamoto-u.ac.jp.
Zahid HM
Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Hashiguchi T
Labolatory of Medical Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan; Department of Virology, Faculty of Medicine, Kyushu University, Fukuoka 812-8582, Japan.
Noda T
Laboratory of Ultrastructural Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan; CREST, Japan Science and Technology Agency, Kawaguchi, Japan.
Kuramoto N
Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Biswas S
Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Matsumoto K
Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Shimizu M
Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Kawanami Y
Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Shimura K
Laboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
Onishi C
Laboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
Muramoto Y
Laboratory of Ultrastructural Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
Suzuki T
Department of Virology, Faculty of Medicine, Kyushu University, Fukuoka 812-8582, Japan.
Sasaki J
Department of Virology, Faculty of Medicine, Kyushu University, Fukuoka 812-8582, Japan.
Nagasaki Y
Division of Infectious Diseases, Clinical Research Institute, National Hospitalization Organization, Kyushu Medical Center, Fukuoka, Japan.
Minami R
Internal Medicine, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.
Motozono C
Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Toyoda M
Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Takahashi H
Department of Respiratory Medicine, Kumamoto City Hospital, Kumamoto 862-8505, Japan.
Kishi H
Department of Respiratory Medicine, Kumamoto City Hospital, Kumamoto 862-8505, Japan.
Fujii K
Department of Respiratory Medicine, Kumamoto City Hospital, Kumamoto 862-8505, Japan.
Tatsuke T
Faculty of Advanced Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan.
Ikeda T
Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan.
Maeda Y
Department of Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Ueno T
Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Koyanagi Y
Laboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
Iwagoe H
Department of Infectious Disease, Kumamoto City Hospital, Kumamoto 862-8505, Japan.
Matsushita S
Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan. Electronic address: shuzo@kumamoto-u.ac.jp.

MeSH

Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCOVID-19Cell LineHEK293 CellsHumansImmunization, PassiveMaleMutationNeutralization TestsProtein DomainsSARS-CoV-2Spike Glycoprotein, Coronavirus

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

34237284

Citation

Kaku, Yu, et al. "Resistance of SARS-CoV-2 Variants to Neutralization By Antibodies Induced in Convalescent Patients With COVID-19." Cell Reports, vol. 36, no. 2, 2021, p. 109385.
Kaku Y, Kuwata T, Zahid HM, et al. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. Cell Rep. 2021;36(2):109385.
Kaku, Y., Kuwata, T., Zahid, H. M., Hashiguchi, T., Noda, T., Kuramoto, N., Biswas, S., Matsumoto, K., Shimizu, M., Kawanami, Y., Shimura, K., Onishi, C., Muramoto, Y., Suzuki, T., Sasaki, J., Nagasaki, Y., Minami, R., Motozono, C., Toyoda, M., ... Matsushita, S. (2021). Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. Cell Reports, 36(2), 109385. https://doi.org/10.1016/j.celrep.2021.109385
Kaku Y, et al. Resistance of SARS-CoV-2 Variants to Neutralization By Antibodies Induced in Convalescent Patients With COVID-19. Cell Rep. 2021 07 13;36(2):109385. PubMed PMID: 34237284.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. AU - Kaku,Yu, AU - Kuwata,Takeo, AU - Zahid,Hasan Md, AU - Hashiguchi,Takao, AU - Noda,Takeshi, AU - Kuramoto,Noriko, AU - Biswas,Shashwata, AU - Matsumoto,Kaho, AU - Shimizu,Mikiko, AU - Kawanami,Yoko, AU - Shimura,Kazuya, AU - Onishi,Chiho, AU - Muramoto,Yukiko, AU - Suzuki,Tateki, AU - Sasaki,Jiei, AU - Nagasaki,Yoji, AU - Minami,Rumi, AU - Motozono,Chihiro, AU - Toyoda,Mako, AU - Takahashi,Hiroshi, AU - Kishi,Hiroto, AU - Fujii,Kazuhiko, AU - Tatsuke,Tsuneyuki, AU - Ikeda,Terumasa, AU - Maeda,Yosuke, AU - Ueno,Takamasa, AU - Koyanagi,Yoshio, AU - Iwagoe,Hajime, AU - Matsushita,Shuzo, Y1 - 2021/06/25/ PY - 2021/03/13/received PY - 2021/05/16/revised PY - 2021/06/18/accepted PY - 2021/7/9/pubmed PY - 2021/7/27/medline PY - 2021/7/8/entrez KW - COVID-19 KW - SARS-CoV-2 KW - mAb KW - neutralizing antibody KW - variant SP - 109385 EP - 109385 JF - Cell reports JO - Cell Rep VL - 36 IS - 2 N2 - Administration of convalescent plasma or neutralizing monoclonal antibodies (mAbs) is a potent therapeutic option for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, SARS-CoV-2 variants with mutations in the spike protein have emerged in many countries. To evaluate the efficacy of neutralizing antibodies induced in convalescent patients against emerging variants, we isolate anti-spike mAbs from two convalescent COVID-19 patients infected with prototypic SARS-CoV-2 by single-cell sorting of immunoglobulin-G-positive (IgG+) memory B cells. Anti-spike antibody induction is robust in these patients, and five mAbs have potent neutralizing activities. The efficacy of most neutralizing mAbs and convalescent plasma samples is maintained against B.1.1.7 and mink cluster 5 variants but is significantly decreased against variants B.1.351 from South Africa and P.1 from Brazil. However, mAbs with a high affinity for the receptor-binding domain remain effective against these neutralization-resistant variants. Rapid spread of these variants significantly impacts antibody-based therapies and vaccine strategies against SARS-CoV-2. SN - 2211-1247 UR - https://www.unboundmedicine.com/medline/citation/34237284/Resistance_of_SARS_CoV_2_variants_to_neutralization_by_antibodies_induced_in_convalescent_patients_with_COVID_19_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2211-1247(21)00783-X DB - PRIME DP - Unbound Medicine ER -